Modification of human immunodeficiency virus type 1 reverse transcriptase to target cells with elevated cellular dNTP concentrations by Jamburuthugoda, Varuni K. et al.
SUNY Geneseo 
KnightScholar 
Biology Faculty/Staff Works Department of Biology 
2006 
Modification of human immunodeficiency virus type 1 reverse 
transcriptase to target cells with elevated cellular dNTP 
concentrations 
V.K. Jamburuthugoda 
P. Chugh 
B. Kim 
Follow this and additional works at: https://knightscholar.geneseo.edu/biology 
Recommended Citation 
Jamburuthugoda V.K., Chugh P., Kim B. (2006) Modification of human immunodeficiency virus type 1 
reverse transcriptase to target cells with elevated cellular dNTP concentrations. Journal of Biological 
Chemistry 281: 13388-13395. doi: 10.1074/jbc.M600291200 
This Article is brought to you for free and open access by the Department of Biology at KnightScholar. It has been 
accepted for inclusion in Biology Faculty/Staff Works by an authorized administrator of KnightScholar. For more 
information, please contact KnightScholar@geneseo.edu. 
Modification of Human Immunodeficiency Virus Type 1
Reverse Transcriptase to Target Cells with Elevated Cellular
dNTP Concentrations*
Received for publication, January 11, 2006, and in revised form, February 8, 2006 Published, JBC Papers in Press, February 22, 2006, DOI 10.1074/jbc.M600291200
Varuni K. Jamburuthugoda‡1, Pauline Chugh§1, and Baek Kim§2
From the §Department of Microbiology and Immunology and the ‡Department of Biochemistry and Biophysics,
University of Rochester Medical Center, Rochester, New York 14642
Retroviruses and DNA viruses utilize cellular dNTPs as sub-
strates for their DNA polymerases during viral replication in
infected cells. However, because of S phase-dependent dNTP bio-
synthesis, the availability of cellular dNTPs significantly varies
among cell types (e.g. dividing versus nondividing cells and normal
versus tumor cells). Here we tested whether alterations in the dNTP
utilization efficiency and dNTP binding affinity of viral DNA poly-
merases can switch viral infection specificity to cell types with dif-
ferent dNTP concentrations. We employed an HIV-1 reverse tran-
scriptase (RT) mutant (Q151N), which is catalytically active only at
high dNTP concentrations because of its reduced dNTP binding
affinity. Indeed, the modified HIV-1 vector harboring the Q151N
mutant RT preferentially transduced tumor cells containing higher
cellular dNTP concentrations than primary cells (e.g. human lung
fibroblasts (HLFs) and human keratinocytes). Although the wild type
HIV-1vector transducedbothHLFsandtumorcells, theQ151Nvector
failed to transduce HLFs and keratinocytes but efficiently transduced
tumor cells. Pretreatment of HLFs with deoxynucleosides, which
increase cellular dNTP pools, enabled the mutant vector to trans-
duce HLFs, suggesting that the transduction failure of the RT
mutant vector to primary cells is because of inefficient reverse tran-
scription in low cellular dNTPenvironments.We also observed that
the Q151N vector expressing herpes simplex virus-thymidine
kinase renders tumor cells sensitive to gancyclovir. This study vali-
dates a novel strategy in which modifications of viral DNA poly-
merases in various vector systems allow the delivery of target genes
exclusively to tumor cells exploiting elevated cellular dNTPconcen-
tration as a tumor cell-specific host factor.
Lentiviruses, including human immunodeficiency virus type 1 (HIV-
1),3 are unique in their ability to infect terminally differentiated or non-
dividing cells such asmacrophage andmicroglia, as well as dividing cells
such as activated CD4 T cells (1, 2). Other retroviruses such as
oncoretroviruses productively infect only dividing cells (1, 3). Because of
their ability to infect nondividing cells, lentivirus-based vector systems
have been developed as useful gene delivery tools for many nondividing
cell types such as neuronal cells (4–6). Several DNA viruses such as
adenovirus and herpes simplex virus (HSV) also have the capability to
replicate in nondividing cells and have been developed as vector systems
targeting nondividing cells (7–9).
Cellular deoxynucleoside triphosphates (dNTPs) serve as substrates
for enzymatic DNA synthesis of retroviruses, as well as many DNA
viruses, and virally encoded DNA polymerases (e.g. reverse tran-
scriptase for retroviruses) catalyze this replication process. Numerous
studies have demonstrated that cancer cells have a higher dNTP content
compared with normal dividing cells because of their uncontrolled cell
division (10–14). Because the dNTP concentration varies between cell
types, the proviral DNA synthesis rate of retroviruses could depend on the
cell type that the virus infects. Using a highly sensitive dNTP assay that we
recently established (2), we determined the dNTP concentrations of
human macrophage and CD4 T cells, two target cell types of HIV-1.
We found that human macrophage (30 nM) have 150–225 times
lower dNTP concentrations than activated CD4 T cells (5 M).
Despite the wide range of dNTP concentrations found in HIV-1 target
cells, we found that HIV-1 RT efficiently synthesizes DNA even at con-
centrations as low as 50 nM because of its tight binding affinity for dNTP
substrates (15).
We recently isolated twoHIV-1 RTmutants, V148I and Q151N, that
specifically exhibit reduced dNTP binding affinity (1/Kd) without a
change in catalysis (kpol) (16, 17). Kinetic and structural analyses sug-
gested that these mutations interfered with H-bond formation between
the side chain of theGln-151 residue and the 3-OHgroup of the incom-
ing dNTP substrate (18). These two mutant RTs showed greatly
reduced DNA synthesis at the low dNTP concentrations found in
macrophage but are as active as wild type at high dNTP concentrations
(2). Furthermore, HIV-1 vectors containing these dNTP binding
mutant RTs failed to transduce macrophage but efficiently infected
HeLa cells, which contain high dNTP levels (2). Therefore, unlike the
wild type HIV-1 vector, whose infectivity is little affected by cellular
dNTP concentration, the transduction of these RT mutant vectors
appears to depend on the availability of cellular dNTP substrates in the
cells that they infect.
Specific gene delivery by replication-incompetent viral vectors to
cancer cells includes the delivery and expression of the following: 1)
toxic proteins (19); 2) correct forms of missing or altered gene products
responsible for tumorigenesis (e.g. p53) (20); and 3) RNA interference
blocking the expression of essential genes (21, 22). Viral vector-based
cancer gene therapy includes the use of well characterized animal virus
systems such as adenoviruses, adeno-associated viruses, retroviruses,
and herpesviruses (4, 6). Another anti-cancer gene therapy strategy is
the use of oncolytic viral vectors that conditionally replicate only in
tumor cells containing tumor-specific genetic alterations. Examples are
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the E1B-deleted adenovirus that replicates only in cells with a loss of p53
function and induces cell killing (23) and adenovirus expressing E1A
from the telomerase reverse transcriptase promoter that is usually acti-
vated in tumor cells (24). These strategies focus on minimizing vector
transduction to normal primary cells. However, some of these tumor-
specific factors are not always found in all tumor cells (e.g. loss of p53
function) (23), which restricts the utility of these oncolytic vectors.
Therefore, identification of new and universal tumor-specific alter-
ations that are essential to transduction and replication of the viral
oncolytic vector systems will improve the efficacy and safety of anti-
cancer vector systems.
In this study, we tested whether the modification of viral DNA poly-
merases, which makes them active only at high dNTP concentrations,
can restrict the infectivity of the viral vector systems specifically to cell
types containing high dNTP concentrations. For this test, we employed
an HIV-1-based vector system harboring a mutant HIV-1 RT with
reduced dNTP binding affinity as a model system. Indeed, this modified
HIV-1 vector was able to deliver genes specifically to cells containing
high dNTP concentrations such as cancer cells withminimum infection
to normal primary cells containing relatively low cellular dNTP concen-
trations such as human lung fibroblasts, keratinocytes (this study), and
macrophage (2).
MATERIALS ANDMETHODS
Plasmids, Cells, and Chemicals—Escherichia coli DH5 (Stratagene)
was used for the construction and amplification of plasmids, and
BL21(DE3) (Novagen) was used for the overexpression of HIV-1 RT
proteins. The HIV-1 packaging-GFP plasmid, pHIV-GFPEnv (a gift
from Dr. Vicente Planelles, University of Utah), expresses all strain
NL4-3 proteins except for Env and Nef, which have been replaced by
EGFP (25). A plasmid expressing vesicular stomatitis virus envelope
protein, pVSV-G, was also obtained from Dr. Planelles. The plasmid
encoding herpes simplex virus thymidine kinase (HSV-TK) was
obtained from Dr. L. A. Loeb (University of Washington). The CHME5
cell line, a human fetal microglia cell line transformed by SV40 large T
antigen (26), was used for viral titering and was a gift from Dr. David
Mock (University of Rochester). CHME5 cells were cultured in Dulbec-
co’s modified Eagle’s medium from CellGro containing 5% fetal bovine
serum (HyClone). TheA549 human lung epithelial tumor cell line was a
gift from Dr. Toru Takimoto (University of Rochester), and these cells
were cultured in Dulbecco’s modified Eagle’s medium with 10% fetal
bovine serum. The 293 FT cell line, obtained from Invitrogen, and the
PANC1 cell line, obtained from ATCC, were both grown in Dulbecco’s
modified Eagle’s medium with 10% fetal bovine serum. The primary
human lung fibroblasts were received as a gift from Dr. Richard Phipps
(University of Rochester) and were cultured in minimal essential
medium (Invitrogen) supplemented with 10% fetal bovine serum
(HyClone) as described previously (27). Restriction enzymes, T7 RNA
polymerase, and T4 polynucleotide kinase were purchased from New
England Biolabs.
Purification of HIV-1 RT Proteins—The wild type and Q151NHIV-1
RT proteins were overexpressed in E. coli BL21 (Novagen, WI) as
described previously (28). The HIV-1 RT expression construct encodes
the full-length HIV-1 RT (HXB2) with a hexahistidine tag at the N
terminus. The hexahistidine-tagged RT was purified using Ni2 chela-
tion chromatography as described previously (17, 29, 30). From 1 liter of
culture, we were able to purify 4 mg of p66/p66 homodimers. To exam-
ine the purity of the RT proteins, 4g of the purified RTs were analyzed
by 10% SDS-polyacrylamide gels using 4 g of 98% pure bovine serum
albumin (Sigma) as a control. The gels visualized by Coomassie staining
were analyzed by a densitometer, and the purified RT proteins showed
similar levels of minor contaminants as the bovine serum albumin con-
trol, suggesting that the RT proteins used in this study must be at least
95% pure.
Assays for dNTP Concentration-dependent DNA Polymerase Activity
of HIV-1 RT Proteins—A 182-nucleotide-long RNA template encoding
the HIV-1 pol sequence was generated by in vitro run-off transcription
from the BamHI-linearized pol donor construct pNL-RT3612-3773
(31) using T7 RNA polymerase as described previously (31). The full-
length transcript was purified on a 6% denaturing polyacrylamide gel.
The 19-nucleotide DNA primer MB22 (5-GCTTGCCAATACTCT-
GTCC-3), complementary to the 3 end of the pol RNA template, was
5-end-labeled using T4 polynucleotide kinase and [-32P]ATP (Amer-
sham Biosciences). Labeled primer (50 fmol) was thenmixed with RNA
template (100 fmol) in 50mMTris-HCl, pH8.0, 1mMEDTA, and 50mM
KCl andwas incubated at 95 °C for 1min. The template/primermixture
was slow-cooled to room temperature to facilitate primer annealing and
refolding of the RNA template. HIV-1 RTs with similar levels of activity
(RTs giving 50% primer extension at high dNTP concentration) were
preincubated for 2 min at room temperature with primer-template, 50
mMTris-HCl, pH 8.0, 50mMKCl, 1mM EDTA, and 1mM dithiothreitol
in a total 12-l reaction volume. Reactionswere initiated by the addition
of 6 mM MgCl2 and deoxynucleoside triphosphates at varying concen-
trations (5–0.05M). After incubation at 37 °C for 5min, reactions were
terminated by the addition of 12l of termination buffer (90% formam-
ide, 10 mM EDTA, pH 8.0, and 0.1% xylene cyanole and 0.1% bromphe-
nol blue). Reaction products were resolved on 6% polyacrylamide-urea
gels and visualized by a PhosphorImager using ImageQuant software
(Amersham Biosciences).
HIV-1 RT-based dNTP Assay with Cellular dNTP Samples—The pro-
tocols for dNTP extraction from cells and the dNTP assaywere performed
as described previously (2). dNTPs extracted from tumor cells and primary
cells were resuspended to 100 and 10l per 1 106 cells.
Pseudotyped HIV-1 Vector Production—pHCMV-VSVG envelope
vector (32) and pHIV-EGFPEnv transfer vector (25), which encodes
theHIV-1NL4-3 genomewith the EGFP gene in place ofHIV-1Nef and
a deletion of the env gene, were used for preparing pseudotyped HIV-1.
TheQ151Nmutationswere cloned into the pD3-EGFP (pNL4-3-based)
vector using overlapping PCR with proper primers that were designed
based on the pNL4-3 RT sequence as described previously (2). Produc-
tion of pseudotyped HIV-1 vectors was then performed as described
previously (2). p24 levels of produced vectors were measured using the
HIV-1 p24 antigen enzyme-linked immunosorbent assay test system
(Beckman Instruments).
Vector Infections and Analysis—All cell types were treated with 10
g/ml Polybrene prior to transduction with either WT or Q151N virus
at an m.o.i. of 5. 48 h post-transduction, cells were washed and visual-
ized by fluorescence microscopy (Leica), using EGFP as an indicator of
transduction efficiency. Following imaging, cells were trypsinized and
fixed in a 0.5% formaldehyde solution for further analysis by FACS. Cell
samples were analyzed by FACS using the FL-1 channel to detect EGFP
expression, and the percentage of transduction was determined using
the Cellquest program (version 3.3; BD Biosciences).
dN Effect Assay—Prior to transduction, cells were treated with 2.5
mM each dN (dA, dC, dT, and dG; Sigma). After 4 h of incubation,
Polybrene was added at 10g/ml, and cells were transduced with either
wild type or Q151N vector at anm.o.i. of 5. 24 h post-transduction, cells
were washed with Dulbecco’s phosphate-buffered saline, and fresh
medium was added. Cells were then incubated for an additional 24 h
Tumor-specific HIV-1 Vector with Reduced dNTP BindingMutant
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before imaging and FACS analysis. All assays were performed in
triplicate.
2LTR Circle PCR—Primers for the amplification of the HIV-1 2LTR
circle DNA were described previously (33, 34). The forward primer
anneals to the 75 bp upstream from the 3 end of the 5-LTR region of
NL4-3 (5-GTGCCCGTCTGTTGTGTGACT-3), and the reverse
primer anneals to the 33 bp downstream of the 5 end of the 3-LTR
region (5-CTTGTCTTCTTTGGGAGTGAATTAGC-3), and the
probe (5-6-carboxyfluorescein-TCCACACTGACTAAAAGGGTCT-
GAGGGATCTCT-carboxytetramethylrhodamine-3) anneals at the
junction of 5–3-LTR region. The human lung fibroblast cells with or
without dN (2.5mM) treatment for 4 h were incubated with wild type or
Q151N vectors with m.o.i. of 5. The cells were harvested at 6, 12, and
24 h post-transduction. The total cellular DNA was extracted using a
genomic extraction kit (Qiagen). The amplification was performedwith
the forward primer (0.9 M), the reverse primer (0.9 M), the probe (1
M), and 300 ng of the extracted cellular DNA using 2 Taqman uni-
versal mix (Applied Biosystems). PCRs were initially incubated at 50 °C
for 2min followed by 95 °C for 15min. Each cycle of the PCR (50 cycles)
was then performed at 95 °C for 15 s followed by 60 °C for 1min. Stand-
ard curves for the quantification of 2LTR were generated by serial dilu-
tion of a known concentration of 2LTRDNA. Standard curve was linear
within 101 to 106 copies of 2LTR DNA.
Coculturing of Primary and Tumor Cells—To culture different pairs
of cell types, themediumof the primary cell type, not the tumor cell line,
was used. For coculturing of the human lung fibroblasts and the lung
epithelial tumor cell line A549s, cells were cultured inminimal essential
medium (Invitrogen) containing 10% fetal bovine serum and trans-
duced with the appropriate vector as described above.
HSV-TK Vector Construction and Gancyclovir (GCV) Sensitivity
Measurement—Wild type and Q151N mutant RT vectors expressing
HSV-were constructed by replacing the EGFP gene with the HSV-
TK gene, yielding pHIV-HSVTKEnv. After production of
WT-HSV-TK and QN-HSV-TK vector as described above, the p24
levels were measured by the HIV-1 p24 enzyme-linked immunosor-
bent assay. Cells were transduced as described above with either
WT-HSV-TK or QN-HSV-TK virus at identical p24 activities. After
48 h post-transduction, cells were washed with Dulbecco’s phos-
phate-buffered saline and either left untreated or treated with two
concentrations of GCV, 5 and 40 g/ml. Cells were treated with
GCV for a period of 5 days, changing the media and adding fresh
GCV every 24 h. After 5 days, cells were trypsinized and counted
using a hemocytometer. The survival of cells following GCV treat-
ment was normalized as a percentage of the cell number of untreated
cells transduced with the same viral vectors.
RESULTS
dNTP Concentration-dependent DNA Polymerization of HIV-1 RT
Proteins—We recently isolated an HIV-1 RT mutant, Q151N, which
exhibits reduced binding affinity to dNTP substrates without altering
catalysis (17). Because of its reduced dNTP binding affinity, the dNTP
binding step of this mutant, which is fast at high dNTP concentrations
(M range), becomes rate-limiting at low dNTP concentrations (e.g. 50
nM).We examined the dNTP concentration-dependent DNA polymer-
ase activity of wild type andQ151NHIV-1 RTs using a primer extension
assay. This assay employed a 5-32P-labeled 19-mer primer (Fig. 1, S)
annealed to a 182-nucleotide-long RNA template encoding the pol gene
of HIV-1 and varying concentrations of dNTPs, which can yield fully
extended products (Fig. 1, F). First, the amount of RT protein showing
50% primer extension at 5 M was determined (Fig. 1, 5). The con-
centrations of the wild type and Q151N RT proteins showing 50%
primer extension at high dNTP concentrations were very similar
(50–60 nM). Next, the same reactions were repeated with decreasing
concentrations of dNTPs. As shown in Fig. 1, the Q151N mutant
showed a dramatic decrease in primer extension even at relatively high
FIGURE 1.dNTP concentration-dependent reverse transcriptionactivity ofHIV-1RT
proteins. A 32P-labeled 19-mer primer (S) annealed to a 182-nucleotide-long RNA tem-
plate encoding a part of the HIV-1 pol gene was extended by wild type (A) and Q151N
mutant (B) HIV-1 RT proteins (50–60 nM) showing 50% of the full extension in a 5-min
reaction (F) at 5 M dNTPs (1st lane). Similar reactions were repeated with decreasing
concentrations of dNTP: 1st to 7th lanes, 5, 2.5, 1, 0.5, 0.25, 0.1, and 0.05M, respectively.
The reactions were analyzed by 6% denaturing gels. The dNTP concentrations observed
in tumor/transformed cells (T) and primary cells (P) are marked (see Fig. 2).
FIGURE 2. dNTP concentrations of human cells. A, HIV-1 RT-based dNTP assay: A
32P-labeled 18-mer primer (S) annealed to a 19-mer template was extended by HIV-1
RT with various dNTP sources, producing the 19-mer product (P). C lane, no dNTP; 2nd
lane, 250 M pure dATP or dCTP; 3rd lane, dNTP extracted from primary HLFs (4  104
cells); 4th lane, HLF with 2.5 mM dN treatment (4 104 cells). B, dNTP concentrations of
human cell types; amounts of dNTPs contained in each cell type were calculated by
plotting the % of the primer extension obtained from the dNTP assay to the standard
curves derived from the dNTP assay reactions with known amounts of pure dNTPs (2).
The dNTP samples from the dN-treated HLFs were properly diluted to obtain primer
extension in the linear range (4–128 fmol) (2). The volume of each cell type used in this
study was measured by confocal microscopy for determining the cellular dNTP concen-
tration of each cell type. The assays were performed in triplicate, and S.D. of each dNTP
was25%. The ranges of the dNTP concentrations indicate the variations between the
four dNTPs.
Tumor-specific HIV-1 Vector with Reduced dNTP BindingMutant
13390 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 281•NUMBER 19•MAY 12, 2006
 by guest on A
ugust 22, 2019
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
dNTP concentrations (e.g. Fig. 1, 3rd lane, 1 M), whereas the wild type
HIV-1 RT maintained significant levels of primer extension even at
concentrations as low as 50–250 nM. This experiment demonstrates
that theQ151NHIV-1 RT dNTP bindingmutant is capable of perform-
ing efficient reverse transcription only at high dNTP concentrations
such as 2.5 and 5 M (Fig. 1, 1st and 2nd lanes).
Cellular dNTP Concentrations of Normal Primary Cells and Tumor
Cells—Employing a highly sensitive dNTP assay that we established
recently (2), we determined the cellular dNTP concentrations of
normal primary HLFs, primary human keratinocytes, and four
human tumor cell lines (a lung epithelial tumor cell line (A549), an
SV40-transformed human fetal microglia cell line (CHME5), an
FIGURE 3. Transduction of HIV-1 vectors con-
tainingwild typeandQ151NRTs tonormaland
tumor cells. A, primary HLFs and A549 human
lung epithelial tumor cells were transduced by an
equal p24 amount (1.5 106 pg) of wild type and
Q151N HIV-1 vectors. The EGFP expression of
transduced cells was analyzed at 48 h post-trans-
duction by fluorescence microscopy. Both bright
field (BF) and dark field (GFP) images are shown. B,
HLFs and transformed human cell lines were
transduced with equal p24 amounts of wild type
and Q151N vectors (3  105 pg for CHME5), and
the transduction efficiency for each cell type was
determined by FACS. The untransduced cells are
shown in gray, and vector-transduced cells are
depicted by the green histograms. Parameters for
gatingwere set so that the untransduced controls
gave only 1% GFP-positive cells according to the
FL-1 channel (x axis). Total cells were gated on the
basis of physical parameters (forward and side
scatter), and the percent GFP-positive cells was
determined. The yaxis corresponds to thenumber
of cells counted during FACS analysis. C, the aver-
age transduction efficiency of each experiment
performed in duplicate and the transduction effi-
ciency ratios between wild type and Q151N
mutant vectors. Standard deviation was10% in
multiple measurements.
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SV40-transformed human kidney epithelial cell line (293FT), and a
human pancreatic epithelial cancer cell line (PANC1)). The dNTP
assay is a single nucleotide incorporation reaction using a 32P-labeled
18-mer primer (Fig. 2A, S, 1st lane, no dNTP) annealed to a 19-mer
DNA template. These template/primers contain single nucleotide 5
template overhangs (see “Materials and Methods”). The four differ-
ent templates contain a different sequence in their 5 overhang,
which can be enzymatically filled with one of the four natural dNTPs
from mixtures extracted from the cell types discussed above, pro-
ducing a 19-mer product (Fig. 2A, P, 2nd lane, with 2.5 mM pure
dNTPs). This assay uses HIV-1 RT as a DNA polymerase and cellular
dNTPs extracted from 4  104 cells (Fig. 2A, 3rd lane). Using
standard curves obtained with known amounts of each dNTP and
cell volumes determined using confocal microscopy (2), the cellular
dNTP concentrations of HLFs and the four human cancer/trans-
formed cell lines were determined. As shown in Fig. 2B, the human
tumor/transformed cell lines tested in this study have10–30 times
higher dNTP concentrations (1–5.7 M) than HLFs (0.1–0.2 M) or
primary human foreskin keratinocytes (0.1–0.6 M). Note that the
Q151NHIV-1 RTmutant protein displayed a dramatically decreased
DNA polymerase activity at the dNTP concentrations equivalent to
those observed in HLFs and keratinocytes, whereas wild type HIV-1
RT still remained relatively active at these low dNTP concentrations
(Fig. 1).
Transduction Efficiency of HIV-1 Vectors Containing Wild Type and
the Q151N dNTP Binding Mutant RT to Various Cell Types—Next, we
tested whether an HIV-1 vector containing the Q151N RT mutant was
able to transduce two normal primary human cell types, HLFs and kera-
tinocytes, and four human tumor cell lines containing low and high
cellular dNTP concentrations, respectively. The HIV-1 vector system
used expresses EGFP, and therefore the transduced cells can easily be
detected via fluorescence analysis. First, HLFs and lung epithelial tumor
cells (A549s) were individually transduced with the same p24 level of
wild type and mutant HIV-1 vectors, and the transduction efficiency
was determined at 48 h post-transduction. As shown in Fig. 3, A and B,
the wild type HIV-1 vector successfully transduced both normal pri-
mary fibroblasts and epithelial tumor cells with similar efficiency. How-
ever, HIV-1 vectors containing the Q151N mutant RT showed very
restricted transduction of normal lung fibroblasts, although they effi-
ciently transduced A549s containing high dNTP concentrations (Fig. 3,
A and B). TheQ151N vector also showed significantly low transduction
efficiency in human keratinocytes, whereas the wild type vector effi-
ciently transduced this primary cell type (Fig. 3C). We also observed
similar transduction differences between wild type and Q151N vectors
in the human pancreatic cancer cell line (PANC1) and the two SV40 T
antigen transformed cell lines (CHME5 and 293FT cells) (Fig. 3C).
Therefore, the data shown in Fig. 3 suggest that, unlike the wild type
HIV-1 vector, themutant vector containing a dNTP bindingmutant RT
preferentially transduced only cells containing high cellular dNTP
concentrations.
Deoxynucleoside (dN) Effect on the Transduction of HIV-1 Vectors to
Primary Cells—We tested whether the restricted transduction of the
Q151NHIV-1 vector to primary human lung fibroblasts was because of
the limited dNTP availability in this cell type. For this test, we treated
cells with dNs, the precursors of dNTPs, which can enhance cellular
dNTP concentrations. First, we determined the dNTP concentration
change upon dN treatment of human lung fibroblasts. As shown in Fig.
2A, the dN (2.5 mM)-treated human fibroblasts showed a large increase
in dNTP levels comparedwith the untreated cells. The dNTP assay with
diluted dNTP samples showed that dN treatment of HLFs increases
the dNTP level by approximately several hundredfold. The calcu-
lated dNTP concentration of HLFs treated with dNs was 20–90 M,
which is15 times higher than that of the dNTP concentration found
in transformed cells (e.g. Fig. 2B, CHME5). Next, we transduced both
dN-treated and untreated human lung fibroblasts with either the wild
type or Q151N vector. As shown in Fig. 4, A and B, the wild type vector
transduced both dN-treated and untreated fibroblasts with similar effi-
ciency. As predicted, the Q151N (Fig. 4, A and B) vector, which showed
very restricted transduction in primary lung fibroblasts, showed greatly
enhanced transduction upon dN treatment. Next, we examined the
proviral DNA synthesis of the Q151N and wild type HIV-1 vectors in
HLFs with or without dN treatment using the HIV-1 2LTR circle-spe-
cific real time PCR assay (Fig. 4C). The 2LTR circle proviral DNA,which
is found in nuclei, is an indicator for the completion of HIV-1 proviral
DNA synthesis. As seen in Fig. 4C, very limited numbers of copies of
2LTR circle DNA were found in untreated HLF cells transduced by the
Q151N vector even at 24 h post-transduction, whereas the dN-treated
HLFs displayed 200-fold higher copy numbers. However, the wild
type vector showed similar copy numbers of 2LTR circle DNA irrespec-
tive of dN treatment, which is consistent with the transduction effi-
ciency demonstrated in Fig. 4A. Thus, the data support that the failure of
the Q151NHIV-1 vector in the transduction of normal human primary
cells is because of the restricted cellular dNTP concentrations in this cell
type.
Transduction of HIV-1 Mutant Vectors to Cocultured Lung Fibro-
blasts and Epithelial Tumor Cells—Next, we tested whether theQ151N
mutant vectors can preferentially transduce tumor cells containing high
dNTP concentrations when tumor cells are cocultured with primary
cells containing low dNTP concentrations. For this test, we employed
cocultured human lung fibroblasts and human lung epithelial tumor
cells, which clearly display their morphological differences. As shown in
Fig. 5A, the wild type vector efficiently transduced both normal lung
fibroblasts (see arrows) and lung epithelial tumor cells. However, the
samem.o.i. of theQ151N (Fig. 5B) vector showed preferential transduc-
tion to epithelial tumor cells.
Specific Killing of Tumor Cells by GCV and Q151N HIV-1 Vector
Expressing HSV-TK—Finally, we tested whether the Q151N HIV-1
vector expressing HSV-TK can induce tumor cell-specific transduc-
tion and killing upon treatment with GCV. Gancyclovir is a nucleo-
side analog that can be phosphorylated by the HSV-thymidine
kinase. Phosphorylated GCV is incorporated into the growing nucle-
otide chain by host DNA polymerase, resulting in chain termination
and eventually cell death. For this test, the wild type and Q151N
vectors expressing HSV-TK were constructed, and these vectors
were used for the transduction of normal human lung fibroblasts and
lung epithelial tumor cells with a p24 level equivalent to that of the
EGFP-expressing vector used in Fig. 3. Following transduction, cells
were either left untreated or treated with GCV at two concentrations
(5 or 40 g/ml) for 5 days. As shown in Fig. 6A, the wild type vector
killed both normal human lung fibroblasts and epithelial tumor cells
upon GCV treatment. In contrast, when the Q151N vector express-
ing HSV-TK (Fig. 6B) was used for transduction, the majority of the
normal human lung fibroblasts survived, whereas the epithelial
tumor cells were efficiently killed upon GCV treatment. The data
support the tumor-specific killing of the Q151N HIV-1 vector
expressing the HSV-TK prodrug.
DISCUSSION
To improve the tumor cell-specific gene delivery of lentiviral vectors,
we employed both a unique tumor-specific host factor, highly elevated
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cellular dNTP concentration, which is associated with the uncontrolled
cell division phenotype of tumor cells, and a modified HIV-1 vector
whose replication capability allows the vector to replicate efficiently
only at high cellular dNTP concentrations. Numerous studies reported
that dividing cells have higher dNTP concentrations than nondividing
cells (10–12). In addition, tumor cells with a deregulated cell cycle and
an accelerated replication cycle have higher cellular dNTP concentra-
tions than normal dividing cells. The HIV-1 vector modification was
achieved by using RT mutants with reduced dNTP binding affinity but
with unaltered catalytic activity. Basically, the dNTP binding affinity of
the RT variant in this modified HIV-1 vector is so low that this vector
can replicate only in cells containing unusually high dNTP concentra-
tions such as those found in tumors. We recently isolated and charac-
terized an HIV-1 RT mutant, Q151N, which fulfills this kinetic and
mechanistic requirement (18).
As shown in a series of experiments in this report, the Q151N HIV-1
vector can efficiently transduce several tumor cell lines, namely the
A549 human lung epithelial tumor cell line and the PANC1 human
pancreatic epithelial tumor cell line (Fig. 3). We also observed that the
Q151N vector showed high gene delivery efficiency for two SV40 T
antigen-transformed human cell lines, CHME5 and 293FT, containing
high dNTP concentrations (Fig. 2B). However, themutantHIV-1 vector
FIGURE 4. Effect of dN treatment on the trans-
duction efficiency of thewild type and Q151N
HIV-1 vectors. Primary HLFs left untreated or
pretreated with 2.5 mM dNs were transduced by
an equal p24 level of wild type and Q151N HIV-1
vectors (1.5 106 pg), and the EGFP expression
of untreated and dN-treated HLF cells trans-
duced by wild type and Q151N vectors was ana-
lyzed by fluorescence microscopy (A) and FACS
(B). The axis labels and gating procedures used
were similar to those described above. The log
copy number of HIV-1 2LTR DNA in dN treated
or untreated HLFs at 6, 12, and 24 h post-trans-
duction with WT or Q151N vector (1.5 106 pg
of p24 level) were determined by real time PCR.
BF, bright field. C, * denotes no 2LTR copies.
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failed to transduce normal primary cells such as human lung fibroblasts
and human foreskin keratinocytes. Unlike this mutant vector, however,
the wild type HIV-1 vector transduced both normal and tumor cells
used in this study with equal efficiency. Infections using wild type and
mutant vectors at an equal p24 level showed very similar infectivity in
CHME5 cells (Fig. 3B), suggesting that there is no significant infectivity
difference between the wild type and mutant vectors in cells with high
dNTP concentrations. This finding is consistent with biochemical
observations that both wild type andmutant HIV-1 RTs showed similar
highDNApolymerase activities at the high dNTP concentrations found
in tumor cells (Fig. 1).
Our recent kinetic and structural studies suggested that the active site
of Q151N mutant RT has lost the interaction with the 3-OH group of
the incoming dNTP substrate, reducing their binding affinity to dNTP
substrates and consequently their dNTP incorporation efficiency, par-
ticularly at low dNTP concentrations (18). In contrast, wild type HIV-1
RT has a uniquely tight dNTP binding affinity, and this tight interaction
with the 3-OH group of dNTPs contributes to efficient DNA synthesis
even at low dNTP concentrations. Therefore, these findings suggest
that the HIV-1 RT interaction with the 3-OH group of dNTP sub-
strates is a key mechanistic element that contributes to the cell type
specificity of HIV-1, which is also important in HIV-1 pathogenesis.
This study demonstrates two lines of evidence that the transduction
failure of the Q151N mutant HIV-1 vector in normal primary cells is
because of the absence of proviral DNA synthesis at the limited cellular
dNTP concentrations found in normal primary cells. First, the pretreat-
ment of human lung fibroblasts with dNs increased cellular dNTP con-
centrations by200-fold compared with untreated cells and promoted
the transduction of the Q151N mutant vector in primary human lung
fibroblasts. Second, very restricted copy numbers of HIV-1 2LTR circle
DNA, which is a molecular indicator for completion of the HIV-1 rep-
lication process, was observed upon the transduction of the mutant
vector to primary lung fibroblasts. However, a significant increase of
2LTR circle DNA copy number was observed when dN-treated lung
fibroblasts were transduced by the Q151N vector. These observations
clearly support that poor dNTP availability was a rate-limiting factor in
the transduction of primary lung fibroblasts by the mutant vector.
Preferential transduction by the Q151N vector to lung epithelial
tumor cells was also observed in the coculture setting with normal lung
fibroblasts. This experiment demonstrates a possible use of these mod-
ifiedHIV-1 vectors to specifically target tumor cells. Because the vectors
used in this study are pseudotyped and only a single round of replication
will occur upon transduction and because the Q151N RT is a high
fidelity mutant (17), the RT contained in the mutant Q151N vector is
highly unlikely to revert back to wild type RT. In addition, the model
gene therapy system comprising the Q151N mutant vector expressing
HSV-TK demonstrated that transduction by this modified vector ren-
ders GCV sensitivity preferentially to tumor cells with minimal cell
death in primary human lung fibroblasts. Interestingly, because theHLF
cells were not killed by the Q151N vector even at 5 days post-transduc-
tion, it is likely that the HSV-TK gene was not expressed in HLF cells
transduced with the Q151N vector during the extended period of the
GCV incubation. The pseudotyped vector used in this study also
includes viral protein R (Vpr), whichwe demonstrated to be responsible
for G2 arrest (35). This G2 arrest eventually leads to cell death of HIV-
1-infected T cells. Therefore, it is possible that the vector used in this
study can also lead to tumor-specific cell death even without the
HSV-TK prodrug.
In conclusion, these results demonstrate that the modified vector
system harboring the viral DNA polymerase mutant with reduced
dNTP binding affinity can be a potential gene delivery system for the
specific transduction of cells with high dNTP concentrations, such as
tumor cells. This study suggests that the identification and use of unique
cellular and virological factors essential for the specificity of viral based
vectors can contribute to the development of safe and effective gene
delivery tools.
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